Trisha Branan

Dr. Trisha Branan

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
PDF file
DHDrayton A. Hammond
Drayton A. Hammond
DODouglas R. Oyler
Douglas R. Oyler
JDJohn W. Devlin
John W. Devlin
JPJacob T. Painter
Jacob T. Painter
SBScott Bolesta
Scott Bolesta
JTJodi Taylor
Jodi Taylor
Objective. To examine perceived motivating factors and barriers (MFB) to postgraduate training (PGT) pursuit among pharmacy students. Methods. Third-year pharmacy students at 13 schools of pharmacy provided demographics and their plan and perceived MFBs for pursuing PGT. Responses were characterized using descriptive statistics. Kruskal-Wallis equality-of-proportions rank tests determined if differences in perceived MFBs existed between students based on plan to pursue PGT. Results. Among 1218 (69.5%) respondents, 37.1% planned to pursue PGT (32.9% did not, 30% were undecided). Students introduced to PGT prior to beginning pharmacy school more frequently planned to pursue PGT. More students who planned to pursue PGT had hospital work experience. The primary PGT rationale was, “I desire to gain more knowledge and experience.” Student debt was the most commonly cited barrier. Conclusion. Introducing pharmacy students early to PGT options and establishing work experiences in the hospital setting may increase students’ desire to pursue PGT.

14 May 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
CDCaroline Derrick
Caroline Derrick
P. Brandon BookstaverP. Brandon Bookstaver
P. Brandon Bookstaver
Kevin LuKevin Lu
Kevin Lu
Christopher M. BlandChristopher M. Bland
Christopher M. Bland
SKSamuel Travis King
Samuel Travis King
JJJulie Ann Justo
Julie Ann Justo
Objectives: There is debate on whether the use of third-generation cephalosporins (3GC) increases the risk of clinical failure in bloodstream infections (BSIs) caused by chromosomally-mediated AmpC-producing Enterobacterales (CAE). This study evaluates the impact of definitive 3GC therapy versus other antibiotics on clinical outcomes in BSIs due to Enterobacter, Serratia, or Citrobacter species. Methods: This multicenter, retrospective cohort study evaluated adult hospitalized patients with BSIs secondary to Enterobacter, Serratia, or Citrobacter species from 1 January 2006 to 1 September 2014. Definitive 3GC therapy was compared to definitive therapy with other non-3GC antibiotics. Multivariable Cox proportional hazards regression evaluated the impact of definitive 3GC on overall treatment failure (OTF) as a composite of in-hospital mortality, 30-day hospital readmission, or 90-day reinfection. Results: A total of 381 patients from 18 institutions in the southeastern United States were enrolled. Common sources of BSIs were the urinary tract and central venous catheters (78 (20.5%) patients each). Definitive 3GC therapy was utilized in 65 (17.1%) patients. OTF occurred in 22/65 patients (33.9%) in the definitive 3GC group vs. 94/316 (29.8%) in the non-3GC group (p = 0.51). Individual components of OTF were comparable between groups. Risk of OTF was comparable with definitive 3GC therapy vs. definitive non-3GC therapy (aHR 0.93, 95% CI 0.51–1.72) in multivariable Cox proportional hazards regression analysis. Conclusions: These outcomes suggest definitive 3GC therapy does not significantly alter the risk of poor clinical outcomes in the treatment of BSIs secondary to Enterobacter, Serratia, or Citrobacter species compared to other antimicrobial agents.

1 January 2020 in Sage Open Medicine
Verified
Journal Article
Open access
PDF file
TBTrisha Branan
Trisha Branan
SSSusan E. Smith
Susan E. Smith
ANAndrea Newsome
Andrea Newsome
RPRebecca Phan
Rebecca Phan
WHW Anthony Hawkins
W Anthony Hawkins
Background: Fluid overload is associated with poor outcomes, but mitigating its occurrence poses significant challenges. Objective: This study sought to assess the impact of hidden fluid volume on fluid overload. Methods: This study was a multi-center, retrospective evaluation of adults admitted to a medical or surgical intensive care unit for at least 72 h. Patients were divided into tertiles (low, moderate, and high) based on the hidden fluid volume received. Hidden fluids were defined as intravenous medications, line flushes, blood products, and enteral nutrition. The primary outcome was the incidence of fluid overload at intensive care unit (day 3). Secondary outcomes included mechanical-ventilation free days and association of hidden fluid volume with fluid overload, length of stay, and mortality. Results: A total of 219 (73 per tertile) were included, with hidden fluid volume comprising ⩽2500, 2501–4400, and >4400 mL in the low, moderate, and high tertiles, respectively. Incidence of fluid overload was significantly different across groups (low: 3%, moderate: 14%, high: 25%; p < 0.001). No difference existed in mechanical-ventilation free days or in-hospital mortality across tertiles. In binary logistic regression, hidden fluid volume received at 3 days was independently associated with fluid overload (odds ratio = 1.40, 95% confidence interval = 1.15–1.70). Conclusion: The volume of hidden fluid volume administered by intensive care unit day 3 independently predicted development of fluid overload.

1 August 2008 in Emergency Medicine Clinics of North America
Verified
Journal Article
Closed access
DVDavid F. Volles
David F. Volles
TBTrisha Branan
Trisha Branan

27 December 2021 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
ACAmber Clemmons
Amber Clemmons
LLLisa Lebovitz
Lisa Lebovitz
MFMike Fulford
Mike Fulford
KGKayleigh Greene
Kayleigh Greene
AFAndrea Franks
Andrea Franks
KPKimberly S Plake
Kimberly S Plake

14 June 2024 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
TBTrisha Branan
Trisha Branan
ADAndrew Darley
Andrew Darley
WHW Anthony Hawkins
W Anthony Hawkins
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.